GlassScriptPhysician profile
Jennifer Black
NPI 1508441239
$18,867.36
in general payments reported to CMS, 2019-2025
30 companies · $3,985 in 2025
The $3,985 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,264 · 2022: $4,255 · 2023: $4,413 · 2024: $3,949 · 2025: $3,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,157.71 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,176.10 | 2021-2025 | |
| Amgen INC. | $2,444.95 | 2021-2025 | Enbrel, Tavneos, Evenity |
| Novartis Pharmaceuticals Corporation | $2,054.93 | 2021-2025 | |
| Ucb, INC. | $1,668.24 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,200.38 | 2021-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $938.64 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $686.84 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $628.79 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.30 | 2021-2025 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $348.26 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $321.27 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $235.29 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $217.28 | 2022-2025 | Tymlos |
| Glaxosmithkline, LLC. | $216.95 | 2021-2025 | Benlysta |
| Genzyme Corporation | $200.00 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $175.42 | 2023-2025 | |
| Organon LLC | $141.37 | 2021-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $136.00 | 2021-2024 | Taltz |
| Octapharma USA, INC. | $135.23 | 2022-2024 | Octagam Immune Globulin (Human) |
| Sanofi-Aventis U.S. LLC | $89.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.91 | 2024-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $71.08 | 2022-2024 | Strensiq |
| Sandoz INC. | $70.89 | 2023-2024 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $59.93 | 2022-2025 | Opsumit, Opsynvi |
| Invivyd INC | $55.41 | 2025 | Pemgarda |
| Janssen Scientific Affairs, LLC | $51.03 | 2024 | Tremfya |
| Boston Scientific Corporation | $24.20 | 2021 | |
| Genentech USA, INC. | $17.58 | 2024 | Actemra |
| Arbor Pharmaceuticals, INC. | $15.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.10 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.